Cellectis (CLLS) Liabilities and Shareholders Equity (2013 - 2026)

Cellectis' Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $289.2 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 20.57% year-over-year to $289.2 million; the TTM figure through Mar 2026 stood at $1.3 billion (down 15.46% YoY), while the FY2025 annual figure was $324.7 million, down 15.34% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $289.2 million, down from $324.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $407.1 million in Q2 2024, with the low at $209.7 million in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $334.3 million (2023), against an average of $320.5 million.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity slumped 32.29% in 2022, then jumped 88.78% in 2024.
• Cellectis' Liabilities and Shareholders Equity stood at $261.2 million in 2022, then gained by 27.97% to $334.3 million in 2023, then gained by 14.74% to $383.5 million in 2024, then fell by 15.34% to $324.7 million in 2025, then slipped by 10.94% to $289.2 million in 2026.
• Business Quant data shows CLLS's Liabilities and Shareholders Equity at $289.2 million in Q1 2026, $324.7 million in Q4 2025, and $343.0 million in Q3 2025.